Carl D. Regillo

1 month ago | eyetube.net | I. Paul Singh |Carl D. Regillo

Innovations in AMD Therapy: Second-Generation Anti-VEGFs I. Paul Singh, MD; and Carl D. Regillo, MD Show Description + In this episode of Innovation Journal Club, Carl Regillo, MD, and I. Paul Singh, MD, discuss outcomes from phase 3 studies of faricimab-svoa (Vabysmo, Genentech) and aflibercept 8 mg (Eyelea HD, Regeneron) in neovascular AMD. According to Dr. Regillo, the data suggests that these agents achieve greater durability and a better drying effect than first-generation anti-VEGF drugs.

Jan 8, 2025 | healio.com | Carl D. Regillo |Anthony DeFino |Christine Klimanskis

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. NEW YORK — In this presentation from OSN New York Retina,Carl D. Regillo, MD, of Wills Eye Hospital, provides guidelines for the treatment of proliferative diabetic retinopathy.

Jan 8, 2025 | healio.com | Carl D. Regillo |Anthony DeFino |Eamon Dreisbach

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Carl D. Regillo, MD, FACS, of Wills Eye Hospital, shares study results from the phase 2 DAVIO 2 trial.

Nov 12, 2024 | healio.com | Carl D. Regillo |Anthony DeFino |Eamon Dreisbach

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Carl D. Regillo, MD, FACS, of Wills Eye Hospital, shares study results from the phase 2 DAVIO 2 trial.

Oct 16, 2024 | hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens

OpinionVideoOctober 16, 2024Anti-VEGF for RVO: The Gold Standard John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.